Abbott isn't bidding for Pfizer's nutritionals unit; NantWorks plans $85.5M, 234-job plant in Indiana;

@FiercePharma: Teva eyes M&A in Asia. Future generics growth will be centered there, CFO says at #JPM12--Bloomberg. News | Follow @FiercePharma

> Abbott Laboratories ($ABT) isn't in the running to buy Pfizer's ($PFE) nutritionals business, a spokeswoman for the company told Bloomberg. News

> Injectables maker NantWorks plans to spend $85.5 million on a new manufacturing facility at Pfizer's former Exubera manufacturing site in Indiana, creating more than 230 jobs in the process. Report

> The Obama administration is likely to block the proposed $716 million merger between Omnicare and PharMerica, sources tell the New York Post. Story

> India chalked up its first year without a new case of polio, the Gates Foundation said. Item

> Novartis ($NVS) board member Pierre Landolt sold 1.41 million shares in the company, a source told Bilanz. Article

> Leo Pharma introduced a patient education and co-pay discount program for its Taclonex psoriasis-fighting products. Release

> Prescriptions for the narcotic painkiller oxycodone increased 82% from 2007 to 2010 in New York state, a new report found. More

> On the heels of new FDA restrictions on antibiotics in livestock, a global animal health organization called for action against abuse of antibiotics in agriculture. Piece

Biotech News

@FierceBiotech: Geron brings in broker to sell stem cell project. CEO thinks resources of biotech cos. at #JPM12 are 'very finite.' Article | Follow @FierceBiotech

@JohnCFierce: Unusually harsh lead on Dow Jones piece re Scangos and Biogen's "decimated" early pipeline. Is the honeymoon over? News | Follow @JohnCFierce

@RyanMFierce Optimer ($OPTR) COO is leaving antibiotics developer to "pursue other interests." Release | Follow @RyanMFierce

> BioCity Scotland creates a new life sciences incubator at Merck site. Item

> Biogen CEO Scangos aims to patch weak points in pipeline. Report

> Geron brings in broker to sell stem cell project. Story

Manufacturing News

> Interview: M+W on lean plants and carmakers. News

> FDA seeks electronic reporting of drug stability tests. Article

> It's 'T' time for contract manufacturers. Report

Vaccines News

> ImmunoCellular starts Phase II trial of brain cancer vaccine. Item

> As India nears polio eradication, researchers ponder new vaccines. News

> Microtest to manufacture ImmusanT's celiac vaccine. Story

And Finally... Running a marathon or half-marathon doesn't boost the risk of suffering a heart attack more than other vigorous exercise does, a New England Journal of Medicine study has found. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.